Dr Yaqi Lyu finished her PhD in 2018 at China Pharmaceutical University in Pharmaceutics focusing on the nano-drug therapy targeting both tumor cell and tumor microenvironment. Then Dr Yaqi Lyu worked as Research Associate in City University of Hong Kong, working on the immunotherapy with platinum-based drug. In 2019, she was awarded the European Commission Marie Curie Fellowship, and joined Queen Mary University of London. Her current research is focused on light-sensitive supramolecular hydrogels for the controlled delivery of therapeutic peptides in vitreous.